Thixotropic Gel Plasma Separator for Viral Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus infections and viral hemorrhagic fever lack effectiveness and safety, with existing therapies showing limited results and risks of transfusion-transmitted infections from convalescent blood products.
Innovation Solution
Development of medical devices and methods for the rapid, efficient, and standardized preparation of convalescent plasma and serum using thixotropic gels and anticoagulants, allowing for the collection of high-purity plasma and serum with minimal cell contamination, which can be used for therapeutic and prophylactic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If convalescent blood products are used for treatment, then therapeutic effect is improved, but risk of transfusion-transmitted infection increases
Solution Approach 1:
The patent extracts the beneficial component (convalescent plasma containing neutralizing antibodies) from the harmful whole blood product. By separating plasma from blood cells through centrifugation and filtration, the invention eliminates transfusion-transmitted infection risks while preserving the therapeutic antiviral antibodies.
2Productivity
If traditional blood separation methods are used, then plasma collection is achieved, but cell contamination remains high
Solution Approach 1:
The patent employs porous filtration membranes with specific pore sizes to separate plasma from blood cells. The porous material allows plasma to pass through while retaining cellular components, achieving high-purity plasma separation without complex equipment.
Solution Approach 2:
The invention replaces traditional mechanical centrifugation methods with a combination of gravity-based separation and porous filtration. This substitution simplifies the separation process while improving plasma purity by removing residual cells that centrifugation cannot eliminate.
3Adaptability or versatility
If standardized preparation methods are not used, then flexibility in treatment is maintained, but treatment efficacy varies
Solution Approach 1:
The patent establishes preliminary standardized protocols for plasma collection, processing, storage, and administration. These pre-defined standards ensure consistent plasma quality and therapeutic efficacy across different treatment cases while maintaining adaptability through controlled variable parameters.
Solution Approach 2:
The invention defines specific parameter ranges for plasma preparation (temperature, pH, antibody concentration, volume) that can be adjusted within controlled limits. This allows flexibility in adapting to different patient needs while ensuring treatment efficacy remains consistent through standardized parameter boundaries.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a safe and effective treatment and prophylaxis for coronavirus infections and viral hemorrhagic fever by enabling the production of high-purity convalescent plasma and serum with reduced cell contamination, improving treatment efficacy and minimizing adverse reactions.
Implementation Method 1
Development of medical devices and methods for the rapid, efficient, and standardized preparation of convalescent plasma and serum using thixotropic gels
Implementation Method 2
allowing for the collection of high-purity plasma and serum with minimal cell contamination
Data Source
AI summary
A container for use in the treatment and/or prophylaxis of viral infections and/or associated conditions prefilled with a thixotropic gel characterized by a density selected from about 1.02 g/cm3 to about 1.05 g/cm3.